Kornimate/medical-research-clean huggingface dataset:
testing the efficiency of karman curette in the treatment of misoprostol failure in women with missed abortion

Conditions: Abortion, Missed

Summary: the purpose of this study is to examine the success rates of karman curettage in completing the abortion after failed recurred treatment with misoprostol for women with missed abortion.


Eligibility criteria:
inclusion criteria: * healthy women diagnosed with missed abortion treated in meir medical center. * the abortion occured during the first trimester of pregnancy. * patients who chose drug therapy (misoprostol), after retained products of conception were evident on ultrasound. exclusion criteria: * patients with mullarian abnormality (i.e. septal uterus, myoma etc.) * patients with significant bleeding * endometrial wall (residua) greater than 20 mm. * known or suspected infection * known clotting defect * women after cesarean section * closed cervix
evaluation of the role of plasma biomarkers in the development of decompensation in patients with cirrhosis .

Conditions: Cirrhosis

Summary: this is a single-center and prospective study to identify specific biomarker in order to predict development of decompensation in cirrhotic patients. the duration of the study is 36 months and it provides a cohort of 200 patients.

at screening, patient will have taken blood samples and performed hepatic vein pressure gradient. after randomization, patient will be seen at follow up every 3 months to do blood sample and every 12 months to undergo hepatic vein pressure gradient , according to the guidelines. in addition, metabolomics analysis will be performed at screening and every 3 months. the results will be analyzed in relation to emergence of decompensation during follow up period, in order to identify specific metabolomics characteristics that may be able to predict decompensation.

Eligibility criteria:
inclusion criteria: * diagnosis of liver cirrhosis * aged between 18 and 75 years * obtaining written informed consent * absence of exclusion criteria exclusion criteria: * diagnosis of hepatocellular carcinoma * presence of portal vein thrombosis * hiv * liver transplantation

Keywords: decompensation deficit metabolomics portal hypertension
an investigational study of gardasil™ (qhpv vaccine) in reducing the incidence of anogenital warts in young men (v501-020)

Conditions: Condylomata Acuminata

Summary: this study was conducted to demonstrate that gardasil™ (quadrivalent human papillomavirus \[qhpv\] vaccine) 1) is well tolerated in young men, 2) reduces incidence of external genital lesions in young men, 3) reduces the incidence of anal intraepithelial neoplasia (ain) or anal cancer in men having sex with men (msm), and 4) reduces incidence of human papillomavirus (hpv) infection in young men. in the 7-month base study participants received randomly assigned qhpv vaccine or placebo at day 1, month 2, and month 6. base study follow-up continued through month 36. in extension 1 (ext1), participants who received placebo or an incomplete qhpv vaccine regimen in the base study were offered qhpv vaccine. participants were followed in ext1 for 7 months. in extension 2 \[ltfu (ext2)\], long-term effectiveness, immunogenicity, and safety of qhpv vaccine were followed up to 10 years following study enrollment. participants who received ≥1 dose of qhpv vaccine in the base study or ext1 were eligible to enroll in ltfu (ext2).


Eligibility criteria:
inclusion criteria: * healthy heterosexual males between the ages of 16 years and 23 years and 364 days. healthy men having sex with men (msm) between the ages of 16 years and 26 years and 364 days. * no clinical evidence of genital lesions suggesting sexually-transmitted disease, and no history of anogenital warts * additional criteria will be discussed with you by the physician exclusion criteria: * concurrently enrolled in a clinical study involving collection of genital specimens * history of known prior vaccination with an hpv vaccine * received an inactivated vaccine within 14 days or a live virus vaccine within 21 days prior to enrollment * history of a severe allergic reaction that required medical intervention * received any immune globulin or blood-derived products within 6 months prior to the first study injection * history of splenectomy, immune disorders, or receiving immunosuppressives * immunocompromised or diagnosed with hiv infection * known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections * history of recent or ongoing alcohol or drug abuse

Keywords: anogenital warts
non steroidal anti-inflammatory drugs in the prevention of bone pain flares after palliative radiotherapy

Conditions: Bone Pain Flare; Bone Metastasis

Summary: solid tumors have the tendency to spread to other organs in around 26% of cases, with many cases involving the bone causing severe bone destruction and pain that reduces patients' quality of life. palliative radiation therapy is used as a standard of care to decrease cancer-related bone pain, as it has been proven to provide pain relief in many patients, either partially or totally, within only a few weeks. however, some patients experience worsening of bone pain especially within the first 10 days after radiation therapy, this is called bone pain flare, and its incidence is estimated to be around 40%. this pain flare tends to further reduce these patients' quality of life considering their main illness, which necessitates its prevention or alleviation. non-steroidal anti-inflammatory drugs (nsaids) which are a key component of the world health organization (who) analgesic options used to alleviate cancer pain have not had a good share of published trials in the prevention of bone pain flares. in this light the investigators aim to conduct a double-blinded, placebo-controlled randomized controlled trial to investigate the effectiveness of nsaids, specifically proxen, in preventing bone pain flares after palliative radiotherapy, and as a secondary endpoint they will compare the quality of life and side effects experienced by patients in either group.


Eligibility criteria:
inclusion criteria: * age 18 years or older * primary solid tumor (any type of solid tumor) * painful bone metastases which are otherwise uncomplicated (no fracture and no neurologic symptoms due to nerve impingement or compression) * baseline pain score on a numeric rating scale (0-10) of at least 2 * stable dose and schedule of narcotic medications prescribed exclusion criteria: * hematologic malignancy * previously irradiated bone * current use of steroids * current use of nsaids which cannot be stopped before randomization * contraindications for nsaids (hypersensitivity, pud, prior gi bleed, ckd, htn, hf, aerd/asthma) * contraindications for ppis
sarcopenia and cachexia in patients with lung cancer

Conditions: Non-small Cell Lung Cancer (NSCLC); Small Cell Lung Cancer (SCLC)

Summary: the philica study investigates whether muscle mass, muscle strength, and muscle function are associated with treatment tolerance, quality of life and survival in patients with lung cancer. it also aims to explore why some patients face challenges in completing their treatment. the findings may contribute to improved strategies for supporting patients and developing more precise and individualized treatment plans in the future.

the philuca prospective cohort study investigates the relationship between sarcopenia, cachexia, and change in muscle parameters with both treatment tolerance, quality of life and survival in patients with lung cancer (n=180). it aims to identify factors associated with difficulties in completing oncological treatment and to elucidate patterns that may inform improved patient support and individualized treatment planning. the study involves non-invasive physical assessments, patient-reported questionnaires, and the analysis of routinely collected medical data. assessments of muscle mass, muscle strength, muscle function, and quality of life are conducted at key time points, including at diagnosis, three months, and six months into treatment. for patients undergoing chemotherapy, muscle strength- and function tests are - in addition to the planned assessments - also performed before each treatment cycle, but no later than six months after the diagnosis. physical tests are performed during routine hospital visits, requiring no additional appointments. body composition analysis is performed using computed tomography scans obtained as part of standard care, without additional imaging procedures. all participants receive standard lung cancer treatment, which may include surgery, chemotherapy, radiation therapy, immunotherapy, targeted therapy, or combinations thereof, based on disease type and stage. the study does not interfere with or modify standard care protocols. participants unwilling or unable to fully participate may still contribute by completing a baseline questionnaire and consenting to the use of medical record data. the study seeks to advance the understanding of how muscle-related parameters influence cancer treatment outcomes. the findings are anticipated to inform strategies for optimizing treatment tolerance, improving patient outcomes, and tailoring supportive care interventions for individuals with lung cancer.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years of age * diagnosed with lung cancer (all types and stages) and scheduled for oncological treatment * more than 3 months expected survival exclusion criteria: * competing cancer * pregnancy * severe physical or cognitive disabilities preventing physical testing and informend consent * not able to read and understand danish

Keywords: sarcopenia cachexia treatment-tolerance survival quality of life lung cancer muscle function muscle strength muscle mass
vitamin d to prevent autism in newborn siblings

Conditions: Autistic Disorder

Summary: the purpose of this study is to determine whether by administering vitamin d to mothers who already have at least one child with autism and who are pregnant, that the vitamin d will prevent the recurrence of autism in the newborn sibling.

the incidence of autism is increasing. also, women of childbearing age are increasingly found to be insufficient/deficient in vitamin d. vitamin d is a neurohormone which is important for development of the child, especially of the child's brain. the primary source of vitamin d is from the sun through one's skin. people have been avoiding the sun because of skin cancer, because of increasing television watching, computer viewing and wearing clothes that cover most of the body. this approach will study whether making the pregnant mother, whose child is at risk for autism because of a previous child with autism, replete with vitamin d will prevent that recurrence of autism in the newborn sibling.

Eligibility criteria:
inclusion criteria: * pregnant mothers who have had at least one child with autism spectrum disorder exclusion criteria: * child with autism must not be from a syndrome such as fragile x syndrome, retts syndrome * mother must be before the third trimester

Keywords: autism pregnancy newborn siblings
single-step transepithelial prk for hyperopia

Conditions: Moderate Hyperopia

Summary: hyperopia is one of the commonest refractive errors encountered in ophthalmology practice. laser in situ keratomileusis (lasik) has been widely used to correct hyperopia especially with the advent of femtosecond laser technology allowing larger flap creation suitable for peripheral hyperopic ablations with resultant predictable, effective, and safe refractive outcomes. however, the encountered lasik flap complications encouraged many surgeons to assess efficiency and safety of surface ablation techniques such as photorefractive keratectomy (prk) to correct hyperopia.

although the initial refractive results of conventional manual or alcohol assisted prk for hyperopia were encouraging, the frequently encountered post-prk complications including undercorrection, overcorrection and regression of the hyperopic error had downgraded the conventional prk as a preferred procedure for hyperopic correction. transepithelial prk provides an alternative technique to uniformly remove the epithelium using the excimer laser to minimize the potential complications caused by mechanical or alcohol assisted epithelial removal in conventional prk. advances in transepithelial prk technology have allowed refractive surgeons to remove the epithelium followed by stromal laser ablation in a single step instead of performing the procedure in 2 separate steps known as phototherapeutic keratectomy-photorefractive keratectomy (ptk-prk). most of the previous studies paid particular attention to investigate the accuracy and safety of single-step transepithelial prk in correcting myopia and myopic astigmatism. the aim of the current study is to evaluate the visual and refractive outcomes of the single-step transepithelial prk procedure in correcting moderate hyperopia and hyperopic astigmatism.

Eligibility criteria:
inclusion criteria: * patients with moderate hyperopia with a hyperopic cycloplegic spherical equivalent between +2 and + 4.5 diopters d. * a steep keratometry (ks) ≤ 46 d. * minimum pachymetry of 500 μm with a calculated residual stromal bed exceeding 350 μm after epithelial and stromal ablation. exclusion criteria: * patients not candidate for corneal refractive surgery, * steep cornea (ks \> 46 d) with an expected postoperative keratometry \> 48 d, * large angle kappa as estimated by chord mu \> 0.25 mm, * hyperopic amblyopia whether unilateral or bilateral with cdva less than 0.2 . logmar acuity, * recent contact lens wear, dry eye disease and autoimmune disorders.

Keywords: single-step prk streamlight prk hyperopia photorefractive keratectomy
the efficacy and safety of the rcmop sequential therapy as a first-line treatment for patients with intermediate-to-high risk diffuse large b-cell lymphoma who had incomplete remission.

Conditions: Diffuse Large B-cell Lymphoma

Summary: a clinical study was conducted to evaluate the efficacy and safety of the rcmop regimen sequential therapy as a first-line treatment for patients with intermediate-to-high risk diffuse large b-cell lymphoma who had incomplete remission.


Eligibility criteria:
inclusion criteria: 1. subjects fully understand and voluntarily participate in this study and sign informed consent 2. age≥18 years old 3. international prognostic index (ipi)\>2 4. expected survival ≥ 3 months 5. dlbcl initially diagnosed by histopathology meets the following subtypes according to the 2016 who classification: (1) germinal center b-cell-like (gcb) subtype; (2) non-germinal center b-cell-like (non-gcb) subtype 6. patients who were evaluated as incomplete remission after 2 cycles of rchop/rcdop for initial treatment 7. at least 1 evaluable or measurable lesion meeting lugano 2014 criteria: nodal lesion: greatest transverse diameter\>1.5cm; extra-nodal lesion: greatest transverse diameter\>1.0cm 8. ecog performance status: 0-1 9. bone marrow function: absolute neutrophil count ≥1.5×10\^9/l, platelet count ≥75×10\^9/l, hemoglobin ≥ 80g/l (patients with bone marrow involvement were judged by the investigator to enter the group) 10. liver and kidney function: serum creatinine ≤ 1.5×uln (upper limit of normal); ast and alt ≤ 2.5×uln (≤ 5×uln for subjects with liver metastases); total bilirubin ≤ 1.5×uln (≤ 3×uln for subjects with liver metastases). exclusion criteria: 1. hypersensitivity to any study drug or its components 2. uncontrolled systemic diseases (such as active infection, uncontrolled hypertension, diabetes, etc.) 3. heart function and disease meet one of the following conditions: (1) long qtc syndrome or qtc interval \> 480 ms; (2) serious and uncontrolled arrhythmias requiring drug treatment, uncontrolled angina with poor drug control and myocardial infarction within 6 months before enrollment; (3) new york heart association grade iii\~iv; (4) cardiac ejection fraction (lvef)\< 45% 4. hepatitis b and hepatitis c active infection (hbv dna above upper limit of normal; hcv antibody positive and hcv rna above upper limit of normal) 5. human immunodeficiency virus (hiv) infection (hiv antibody positive) 6. subjects with other malignant tumors past or present (except for non-melanoma skin basal cell carcinoma, breast/cervical carcinoma in control, and other malignant tumors that have been effectively controlled without treatment within the past five years) 7. subjects suffering from primary or secondary central nervous system (cns) lymphoma 8. pregnancy, lactation and patients of childbearing age who are unwilling to take contraceptive measures 9. mental patients or those who cannot obtain informed consent 10. unsuitable subjects for this study determined by the investigator.
uterocervi̇cal angle measurement in spontaneous preterm birth (uamspb)

Conditions: Preterm Labor

Summary: i̇n this study study; between august 2018 and august 2019, the ministry of health, medeniyet university, göztepe training and research hospital, gynecology and obstetrics clinic will be included for routine control purposes, single pregnancies between 16-24 weeks and no known risk factors for preterm delivery . each participant will be given written and verbal information about the work and will be informed. uterocervical angle measurement; dorsolithotomy, using a sterilized vaginal ultrasonic probe. it will be seen that the distance between the internal cervical os and the external cervical os is inclusive of the cervical isthmus that can be seen with the anterior uterine wall. the first line will be drawn between the internal cervical os and the external cervical os. the second line will be drawn as passing through the internal cervical ostia, parallel to the anterior uterine wall. the angle between the two lines on the internal cervical vertebra will be measured. patients will be followed up until the end of the 37th gestational week. the gestation week they are giving birth will be recorded. patients were then classified as before and after 37 gestational weeks and uterocervical angle measurements between 16-24 gestational weeks were compared.


Eligibility criteria:
inclusion criteria: 1. patients who did not have complaints between december 2017 and august 2018, who went to polyclinic because of routine control 2. patients who had a pregnancy between 16-24 weeks 3. patients with singleton pregnancy 4. patients with a cervical length of 25 mm or more exclusion criteria: 1. patients with preterm labor history (under 37 weeks) in previous pregnancy 2. patients with premature rupture of membranes in current pregnancy 3. patients with past uterine cervical surgery (conization, leep) as a cause of premature birth 4. patients with preterm birth 5. placenta anomalies present pregnancy 6. patient with retrovert uterus, uterine fibroid of lower segment

Keywords: uterocervical angle preterm labor
a study of patients with primary open angle glaucoma or ocular hypertension switched to lumigan® ud monotherapy for medical reasons

Conditions: Glaucoma, Primary Open Angle; Ocular Hypertension

Summary: the study will evaluate patients diagnosed with primary open angle glaucoma or ocular hypertension who are switched to lumigan® ud monotherapy for medical reasons in accordance with physician standard clinical practice. all treatment decisions lie with the physician.


Eligibility criteria:
inclusion criteria: * diagnosed with primary open-angle glaucoma or ocular hypertension * previously prescribed intraocular pressure (iop)-lowering medication with insufficient iop control and is now being switched to lumigan® ud for medical reasons exclusion criteria: * none
mapping genes for type 2 (non-insulin dependent) diabetes mellitus

Conditions: Genetic Variation; Diabetes

Summary: the aim of the project is to positionally clone susceptibility genes for niddm. patients will be ascertained in finland from previous health surveys and hospital discharge records. approximately 400 affected sib pairs will be collected. families will be chosen who have, at most, one parent with niddm no history of iddm. a clinical examination will be undertaken on family members and blood drawn for dna isolation. covariates such as body weight, blood pressure, lipid levels and urinary albumin will also be measured. the unaffected spouse and children of a subset of probands will be invited to undergo a frequently-sampled intravenous glucose tolerance test (fsigt) to measure parameters of pancreatic function and peripheral insulin resistance (ir). a number of unrelated elderly non-diabetic subjects will also be identified to conduct a population-based association analysis. the fsigt analysis will be performed in los angeles. the dna will be shipped to bethesda where a total genomic scan will be performed using semi-automated fluorescence-based genotyping technology. data from bethesda, los angeles and finland will be sent to ann arbor where parametric and non-parametric methods will be used to analyse both discrete traits such as niddm and intermediate traits like ir....

the finland-united states investigation of niddm (fusion) study is a long-term effort to identify susceptibility genes for type 2 diabetes (t2d) and associated quantitative traits. this involves the phenotyping and dna analysis of thousands of individuals living in finland, utilizing a study design that was originally based on affected sib pairs. the majority of these samples have already been subjected to a genome scan using microsatellite markers and the original fusion samples. additionally, thousands of other northern european cases and controls have been subjected to genome-wide association (gwa) analysis and/or fine mapping as part of the fusion study. more recently, the opportunity provided by the lowered sequencing costs have allowed targeted and/or whole genome sequencing of many of these individuals.

Eligibility criteria:
* no eligibility criteria listed.

Keywords: monogenic diabetes type 2 diabetes mellitus qtl
assessment of myocardial injury in simultaneous pancreas and kidney transplantation

Conditions: Simultaneous Pancreas-kidney Transplantation; Diabetic Cardiomyopathy

Summary: diabetic cardiomyopathy( dcm) is a major complication of diabetes and is a common cardiovascular complication independent of coronary artery disease and hypertension．trial to assess of myocardial injury in recipients of simultaneous pancreas and kidney transplantation by nuclear magnetic t２ mapping technology.

1. evaluate the changes of myocardial injury before and after spk by cardiac magnetic resonance imaging (cmr), 2. evaluate the value of spk in the repair of myocardial injury by comparing with the single renal transplant in recipients with diabetic nephropathy.

Eligibility criteria:
inclusion criteria: 1. patients with type 2 diabetes were treated with spk; 2.no definite history of cardiovascular diseases (such as congenital heart disease, coronary heart disease, cardiomyopathy or valvular heart disease, etc.); 3. preoperative hemodialysis 4. no history of heart failure exclusion criteria: 1. contraindications in cardiac magnetic resonance imaging；2.poorly controlled hypertension；3.cmr examination revealed marked hypertrophy of the left ventricular myocardium

Keywords: spk ,dcm,cmr